Overview of Whole Genome Synthesis MarketThe global Whole Genome Synthesis Market is valued at USD 2.41 Billion in 2024 and is projected to reach a value of USD 12.21 Billion by 2035 at a CAGR ...

Both CRSP and NTLA are advancing in vivo gene editing therapies targeting large markets, with financial stability supporting ...

Intellia Therapeutics will find it challenging to survive now that its CRISPR gene-editing treatment has been tied to severe, ...

CRISPR Therapeutics could maintain that momentum thanks to progress with its leading candidates. Spotify Technologies' deep ...

Intellia Therapeutics said it is pausing two late-stage CRISPR gene-editing trials after a patient in one study was hospitalized with liver damage.

CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

A lthough still in its early days, CRISPR has already been called the most powerful scientific tool of the century. Using ...

As artificial intelligence usage soars, so has demand for data centers to power it. Cities are grappling with what that means for their residents’ electricity bills and the reality of living in the ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min A small S.F. biotech with ties ...

If you use the Discord app, your personal data may have been stolen in a recent data breach. In a recent press release, the company highlights an incident involving one of its third-party customer ...

SAN FRANCISCO, Oct 8 (Reuters) - Cisco Systems (CSCO.O), opens new tab launched on Wednesday a new networking chip designed to connect artificial intelligence data centers, with the cloud computing ...

CRISPR Therapeutics and BioNTech have climbed along with many of their peers over the past week. Both are innovative biotechs with catalysts that could drive their stocks higher in the next few years.